Cargando…

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazorra, Zaima, Lavastida, Anabel, Concha-Benavente, Fernando, Valdés, Anet, Srivastava, Raghvendra M., García-Bates, Tatiana M., Hechavarría, Esperanza, González, Zuyen, González, Amnely, Lugiollo, Martha, Cuevas, Iván, Frómeta, Carlos, Mestre, Braulio F., Barroso, Maria C., Crombet, Tania, Ferris, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474456/
https://www.ncbi.nlm.nih.gov/pubmed/28674498
http://dx.doi.org/10.3389/fphar.2017.00382
_version_ 1783244447426805760
author Mazorra, Zaima
Lavastida, Anabel
Concha-Benavente, Fernando
Valdés, Anet
Srivastava, Raghvendra M.
García-Bates, Tatiana M.
Hechavarría, Esperanza
González, Zuyen
González, Amnely
Lugiollo, Martha
Cuevas, Iván
Frómeta, Carlos
Mestre, Braulio F.
Barroso, Maria C.
Crombet, Tania
Ferris, Robert L.
author_facet Mazorra, Zaima
Lavastida, Anabel
Concha-Benavente, Fernando
Valdés, Anet
Srivastava, Raghvendra M.
García-Bates, Tatiana M.
Hechavarría, Esperanza
González, Zuyen
González, Amnely
Lugiollo, Martha
Cuevas, Iván
Frómeta, Carlos
Mestre, Braulio F.
Barroso, Maria C.
Crombet, Tania
Ferris, Robert L.
author_sort Mazorra, Zaima
collection PubMed
description Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab’s capacity of killing tumor cells by antibody dependent cellular cytotoxicity (ADCC) and to induce an immune response in cancer patients have not been studied. ADCC-induced by nimotuzumab was determined using a (51)Cr release assay. The in vitro effect of nimotuzumab on natural killer (NK) cell activation and dendritic cell (DC) maturation and the in vivo frequency of circulating regulatory T cells (Tregs) and NK cells were assessed by flow cytometry. Cytokine levels in supernatants were determined by ELISA. ELISpot was carried out to quantify EGFR-specific T cells in nimotuzumab-treated head and neck cancer (HNSCC) patients. Nimotuzumab was able to kill EGFR+ tumor cells by NK cell-mediated ADCC. Nimotuzumab-activated NK cells promoted DC maturation and EGFR-specific CD8+ T cell priming. Interestingly, nimotuzumab led to upregulation of some immune checkpoint molecules on NK cells (TIM-3) and DC (PD-L1), to a lower extent than another EGFR mAb, cetuximab. Furthermore, circulating EGFR-specific T cells were identified in nimotuzumab-treated HNSCC patients. Notably, nimotuzumab combined with cisplatin-based chemotherapy and radiation increased the frequency of peripheral CD4+CD39+FOXP3+Tregs which otherwise were decreased to baseline values when nimotuzumab was used as monotherapy. The frequency of circulating NK cells remained constant during treatment. Nimotuzumab-induced, NK cell-mediated DC priming led to induction of anti-EGFR specific T cells in HNSCC patients. The association between EGFR-specific T cells and patient clinical benefit with nimotuzumab treatment should be investigated.
format Online
Article
Text
id pubmed-5474456
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54744562017-07-03 Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients Mazorra, Zaima Lavastida, Anabel Concha-Benavente, Fernando Valdés, Anet Srivastava, Raghvendra M. García-Bates, Tatiana M. Hechavarría, Esperanza González, Zuyen González, Amnely Lugiollo, Martha Cuevas, Iván Frómeta, Carlos Mestre, Braulio F. Barroso, Maria C. Crombet, Tania Ferris, Robert L. Front Pharmacol Pharmacology Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab’s capacity of killing tumor cells by antibody dependent cellular cytotoxicity (ADCC) and to induce an immune response in cancer patients have not been studied. ADCC-induced by nimotuzumab was determined using a (51)Cr release assay. The in vitro effect of nimotuzumab on natural killer (NK) cell activation and dendritic cell (DC) maturation and the in vivo frequency of circulating regulatory T cells (Tregs) and NK cells were assessed by flow cytometry. Cytokine levels in supernatants were determined by ELISA. ELISpot was carried out to quantify EGFR-specific T cells in nimotuzumab-treated head and neck cancer (HNSCC) patients. Nimotuzumab was able to kill EGFR+ tumor cells by NK cell-mediated ADCC. Nimotuzumab-activated NK cells promoted DC maturation and EGFR-specific CD8+ T cell priming. Interestingly, nimotuzumab led to upregulation of some immune checkpoint molecules on NK cells (TIM-3) and DC (PD-L1), to a lower extent than another EGFR mAb, cetuximab. Furthermore, circulating EGFR-specific T cells were identified in nimotuzumab-treated HNSCC patients. Notably, nimotuzumab combined with cisplatin-based chemotherapy and radiation increased the frequency of peripheral CD4+CD39+FOXP3+Tregs which otherwise were decreased to baseline values when nimotuzumab was used as monotherapy. The frequency of circulating NK cells remained constant during treatment. Nimotuzumab-induced, NK cell-mediated DC priming led to induction of anti-EGFR specific T cells in HNSCC patients. The association between EGFR-specific T cells and patient clinical benefit with nimotuzumab treatment should be investigated. Frontiers Media S.A. 2017-06-19 /pmc/articles/PMC5474456/ /pubmed/28674498 http://dx.doi.org/10.3389/fphar.2017.00382 Text en Copyright © 2017 Mazorra, Lavastida, Concha-Benavente, Valdés, Srivastava, García-Bates, Hechavarría, González, González, Lugiollo, Cuevas, Frómeta, Mestre, Barroso, Crombet and Ferris. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Mazorra, Zaima
Lavastida, Anabel
Concha-Benavente, Fernando
Valdés, Anet
Srivastava, Raghvendra M.
García-Bates, Tatiana M.
Hechavarría, Esperanza
González, Zuyen
González, Amnely
Lugiollo, Martha
Cuevas, Iván
Frómeta, Carlos
Mestre, Braulio F.
Barroso, Maria C.
Crombet, Tania
Ferris, Robert L.
Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
title Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
title_full Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
title_fullStr Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
title_full_unstemmed Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
title_short Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
title_sort nimotuzumab induces nk cell activation, cytotoxicity, dendritic cell maturation and expansion of egfr-specific t cells in head and neck cancer patients
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474456/
https://www.ncbi.nlm.nih.gov/pubmed/28674498
http://dx.doi.org/10.3389/fphar.2017.00382
work_keys_str_mv AT mazorrazaima nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT lavastidaanabel nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT conchabenaventefernando nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT valdesanet nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT srivastavaraghvendram nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT garciabatestatianam nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT hechavarriaesperanza nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT gonzalezzuyen nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT gonzalezamnely nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT lugiollomartha nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT cuevasivan nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT frometacarlos nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT mestrebrauliof nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT barrosomariac nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT crombettania nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients
AT ferrisrobertl nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients